THIS IS A MULTI-CENTER, SINGLE ARM, OPEN LABEL STUDY INTENDED TO PROVIDE EXPANDED ACCESS TO PLERIXAFOR FOR PATIENTS WITH NON-HODGKIN'S LYMPHOMA (NHL), HODGKIN'S DISEASE (HD) OR MULTIPLE MYELOMA (MM) WHO ARE TO RECEIVE TREATMENT WITH AN AUTOLOGOUS PERIPHERAL STEM CELL TRANSPLANT.: